Referral Form for Hereditary Cancer Panel Testing

West of Scotland Centre for Genomic Medicine, Level 2B, Laboratory Medicine, Queen Elizabeth University Hospital, 1345 Govan Road, Glasgow, G51 4TF, Telephone: 0141 354 9300

Patient Details							
Surname:	Forename:		DOB:	Sex: M	F	U	
CHI No:	Postcode:		Pedigree/Ref No:	:			
Referring Clinician							
Clinician Name:		Speciality:					
Telephone:		Email:					
Clinician Address:							
It is the referring clinician's responsibility to obtain informed consent from the patient/carer for the test and for storage or any future test.							

I CONFIRIVI THAT APPROPRIATE CONSENT	Date:		
Sample Taken By:	Sample Date:	Sample Times	
Sample Taken by:	Sample Date.	Sample Time:	

Clinical Indication

Panel Request – please select ONE panel only

Select	Panel	Genes		
	Breast Cancer	ATM, BRCA1 ⁺ , BRCA2 ⁺ , CHEK2 [*] , PALB2, PTEN, RAD51C, RAD51D,		
	(Mainstream Referral)	STK11, TP53		
	Ovarian Cancer	BRCA1 [†] , BRCA2 [†] , BRIP1, MLH1 [‡] , MSH2 [‡] , MSH6 [‡] , PALB2,		
	(Mainstream Referral)	RAD51C, RAD51D		
	Breast/Ovarian Cancer	ATM, BRCA1 ⁺ , BRCA2 ⁺ , BRIP1, CHEK2 [*] , MLH1 [‡] , MSH2 [‡] ,		
	(Requires authorisation from Clinical Genetics)	MSH6‡, PALB2, PTEN, RAD51C, RAD51D, STK11, TP53		
	Breast/Ovarian/Colorectal Cancer APC, ATM, BMPR1A, BRCA1 [†] , BRCA2 [†] , BRIP1, CHEK2 [*] ,			
	(Requires authorisation from Clinical Genetics)	MLH1‡, MSH2‡, MSH6‡, MUTYH, NTHL1, PALB2, PMS2§,		
		POLD1, POLE, PTEN, RAD51C, RAD51D, SMAD4, STK11, TP53		
	Skin Cancer	BRCA2 ⁺ , CDK4, CDKN2A, POT1, BAP1		
	Pancreatic Cancer	BRCA2 [†] , CDK4, CDKN2A, MLH1 [‡] , MSH2 [‡] , MSH6 [‡] , PALB2,		
		STK11, TP53		

Analysis and reporting of variants within the above genes is as recommended by the UKCGG CanVIG-UK Exception Variant Reporting list https://www.ukcgg.org/information-education/exceptional-variantsgene-specific-variant-reporting/

FOR LAB USE ONLY			

PRE-68 Revision 4 Issue Date: 18/12/2024 Page 1 of 1

 $^{^*}$ CHEK2 analysis is restricted to exons 1 to 9 plus the common c.1100delC variant due to the presence of a pseudogene

[†]Dosage analysis also performed for BRCA1 and BRCA2 genes;

[‡]Dosage analysis for MLH1, MSH2 and MSH6 is available in cases where MMR loss of staining has been detected

[§]PMS2 analysis restricted to exons 1-10 due to the presence of the PMS2CL pseudogene; analysis of exons 11-15 by long range PCR is available when PMS2 testing is indicated